Hyperion Therapeutics (HPTX) IPO Trades Slightly Higher

Article Stock Quotes (1) Comments (0)

The IPO for Hyperion Therapeutics (Nasdaq: HPTX) opened at $10.50 after pricing 5,000,000 shares at $10, shares have since drifted lower - last trading at $10.16.

Leerink Swann LLC and Cowen and Company, LLC are serving as joint book-running managers for the proposed offering. Needham & Company, LLC is acting as a co-manager for the proposed offering.

Hyperion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion is developing Ravicti™ (glycerol phenylbutyrate) for two orphan indications: urea cycle disorders (UCD) and hepatic encephalopathy

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• NanoString (NSTG) Files $86.25M IPO
• Compuware's (CPWR) Covisint Files IPO
• Semi-Annual Changes to the NASDAQ Biotechnology Index

Create E-mail Alert Related Categories

IPOs

Related Entities

Needham & Company, Cowen & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?